Otsuka Submits NDA For TB Drug Delamanid in Europe
This article was originally published in PharmAsia News
Executive Summary
Otsuka Pharmaceutical Co. Ltd has filed a new drug application for anti-tuberculosis delamanid (OPC-67683) in Europe. The agent is to treat patients with multi-drug resistant TB.